ProPhase Labs, Inc. Marketable Securities (Current)
ProPhase Labs, Inc. (PRPH) had Marketable Securities (Current) of $0 as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-06-01
- 2025-12-31: Marketable Securities, Current $0.00.
- 2024-12-31: Marketable Securities, Current $3.13M; Marketable Securities, Current as first filed $0.00.
- 2024-09-30: Marketable Securities, Current $2.00K.
- 2024-06-30: Marketable Securities, Current $1.00K.
| Period end | Marketable Securities, Current | Marketable Securities, Current as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 | |
| 2024-12-31 | $3.13M 10-K · filed 2026-06-01 | $0.00 10-K · filed 2025-04-01 |
| 2024-09-30 | $2.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $58.00K 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $3.13M 10-K · filed 2025-04-01 | |
| 2023-09-30 | $2.56M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $5.28M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $5.95M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $8.33M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $3.68M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $3.54M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $3.54M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $8.78M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $14.11M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $18.09M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $3.53M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $1.64M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $1.40M 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $3.34M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $840.00K 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $926.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $3.76M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $4.68M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $4.23M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $6.69M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $6.87M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $6.78M 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $18.33M 10-Q/A · filed 2018-08-20 | |
| 2017-12-31 | $18.77M 10-K · filed 2019-03-26 | |
| 2017-09-30 | $23.64M 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |